Estrogen started within 10 years of Menopause reduces CV risk. This should be HEADLINE News.

Current evidence suggests that hormone therapy initiated within a decade of the onset of perimenopause has been associated with numerous long-term health benefits, including reduced vasomotor symptoms, without significantly affecting atherosclerotic cardiovascular disease among younger postmenopausal women aged 50 to 59 years.¹ Hormone therapy has also been associated with a 25% to 50% reduction in fatal cardiovascular events² (the leading cause of death in women), a 50% to 60% reduction in bone fractures,³ a 64% reduction in cognitive decline,⁴ and a 35% decreased risk of Alzheimer disease. This should be headline news to all women. Cardiovascular disease is the number one killer of men and women.

Martin A. Makary, MD, MPH, US Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993 (commissionersoffice@fda.hhs.gov)